CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 139 enrolled
Drug / intervention
Trim/ Sulfa DS +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00822692
NCT00822692N/ACompleted
CompareCT.gov

Prospective Randomized Double Blind, Placebo-Controlled Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection on 30 Day Recurrence Rates.

59th Medical Wing·interventional·Posted Jan 14, 2009·Updated Dec 21, 2015

In Brief

A clinical study evaluating Trim/ Sulfa DS and placebo for Abscess and Methicillin-Resistant Staphylococcus Aureus Infection. Completed, enrolled 139 participants across 1 site.

Detailed Summary

Patients will be enrolled in a multi-center study (Wilford Hall Medical Center and Brooke Army Medical Center) to prospectively evaluate outcome after treatment for an uncomplicated skin abscess.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAbscess, Methicillin-Resistant Staphylococcus Aureus Infection
CountriesUnited States
CollaboratorsU.S. Air Force Office of the Surgeon General, Emergency Medicine Foundation

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 14, 2009
Enrollment StartJul 1, 2008
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.5 years ago

Interventions

Trim/ Sulfa DSdrug

bactrim DS (800/160) two tablets PO BID x 7 days

placebodrug

matched placebo 2 pills PO BID x 7 days